Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.78 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.57 |
| ▸ | CPA1 | P15085 | 1/20 | 0.56 |
| ▸ | CPA2 | P48052 | 1/20 | 0.56 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | PAM | P19021 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | FURIN | P09958 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550453 | 1.00 | GNPAT (0.78) | GNPATITGB3ITGA2BCPA1CPA2 | |
| SCHEMBL3801759 | 1.00 | GNPAT (0.78) | GNPATITGB3ITGA2BCPA1CPA2 | |
| SCHEMBL8933580 | 1.00 | GNPAT (0.78) | GNPATITGB3ITGA2BCPA1CPA2 | |
| SCHEMBL29368954 | 1.00 | GNPAT (0.78) | GNPATITGB3ITGA2BCPA1CPA2 | |
| SCHEMBL30698071 | 0.96 | GNPAT (0.80) | GNPATITGB3ITGA2BCPA1CPA2 | |
| SCHEMBL31181171 | 0.93 | GNPAT (0.69) | GNPATITGB3ITGA2BCPA1CPA2 | |
| SCHEMBL15862955 | 0.92 | GNPAT (0.67) | GNPATITGB3ITGA2BCPA1CPA2 | |
| SCHEMBL1711591 | 0.90 | GNPAT (0.63) | GNPATERAP2LNPEPCPB2ECE1 | |
| SCHEMBL1711765 | 0.90 | GNPAT (0.63) | GNPATERAP2LNPEPCPB2ECE1 | |
| SCHEMBL1711769 | 0.90 | GNPAT (0.63) | GNPATERAP2LNPEPCPB2ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705045-B2 | compounds comprising a specifier linked to two or more of the same or different leaving groups via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release two or more leaving groups | SYNTARGA, B.V. (NL) | 2010-04-27 | — | — | US | claimed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | claimed |
| US-20080213339-A1 | Pharmaceutical Composition Containing Indometacin and/or Acemetacin | DROSSAPHARM AG (CH) | 2008-09-04 | — | — | US | claimed |
| EP-1912621-A1 | PHARMACEUTICAL COMPOSITION CONTAINING INDOMETACIN AND/OR ACEMETACIN | Drossapharm AG (CH) | 2008-04-23 | — | — | EP | claimed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | claimed |
| WO-2007014476-A1 | PHARMACEUTICAL COMPOSITION CONTAINING INDOMETACIN AND/OR ACEMETACIN | DROSSAPHARM AG (CH) | 2007-02-08 | — | — | WO | claimed |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | SYNTARGA B.V. (NL) | 2006-06-01 | — | — | US | claimed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | claimed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | claimed |
| EP-1370298-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | Syntarga B.V. (NL) | 2003-12-17 | — | — | EP | claimed |
| WO-2002083180-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA B.V. (NL) | 2002-10-24 | — | — | WO | claimed |
| EP-0961619-A4 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL MYERS SQUIBB CO (US) | 2001-09-26 | — | — | EP | claimed |
| EP-0961619-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1998013059-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-02 | — | — | WO | claimed |
| JP-2108697-A | — | — | None | — | — | JP | disclosed |
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | disclosed |
| EP-0961619-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998013059-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-02 | — | — | WO | disclosed |
| JP-H02108697-A | DIPEPTIDE DERIVATIVE AND PEPTIDE SWEETENER CONTAINING THE SAME | KANEGAFUCHI CHEM IND CO LTD | 1990-04-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213339-A1 | Pharmaceutical Composition Containing Indometacin and/or Acemetacin | ACE, IDO1, CMA1 | GNPAT 707/4885ITGB3 3747/4885ITGA2B 4527/4885 |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | DNPEP, GUSB, APEH | GNPAT 1352/4885ITGB3 4631/4885ITGA2B 4579/4885 |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | PLG, KLK1, PKM | GNPAT 3326/4885ITGB3 3124/4885ITGA2B 1886/4885 |
| US-20250263393-A1 | FAP INHIBITORS | FAP, APC, FIBP | GNPAT 225/4885ITGB3 3672/4885ITGA2B 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.